



A Comprehensive Literature Review of The Role Of Leptin In The Pathogenesis Of Systemic Lupus Erythematosus

¹ Erick Persson Jeffry, ¹ Charles Sanjaya Seikka

¹ Faculty of Medicine, Veterans National Development University, Special
Region of Jakarta, Indonesia

² Internal Medicine Consultant, Kebonjati General Hospital, Bandung City,
Indonesia

Correspondence : erick.persson86@gmail.com

Article History :

Received date : 2024/10/21

Revised date : 2024/11/09

Accepted date : 2024/12/12

Published date : 2025/01/08



Copyright: © 2024 by the
authors. Submitted for possible
open access publication under
the terms and conditions of the
Creative Commons Attribution
(BY NC) license
(<https://creativecommons.org/licenses/by-nc/4.0/>).

E-ISSN :

ISSN 3048-1368



P-ISSN :

ISSN 3048-1376



ABSTRACT

Background: The exploration of leptin's role in the pathogenesis of systemic lupus erythematosus (SLE) has garnered increasing attention in recent years, as evidenced by a series of studies that delve into the multifaceted relationships between this adipokine and autoimmune processes. **Literature Review:** Initial findings by (Francisco et al., 2018) suggest that leptin not only acts as an inflammatory marker but also plays a significant role in modulating immune responses, with leptin deficiency in mouse models protecting against autoantibody production and renal disease. (B. Taylor, 2021) expands on the pro-inflammatory effects of leptin, particularly its role in promoting Th1 and Th17 responses while diminishing Treg activity, a dysregulation observed in various autoimmune diseases, including SLE. The systematic review by highlights the complexity of leptin's role, indicating that it may function both as a pro-inflammatory and regulatory factor in SLE. This duality suggests that further research is needed to clarify the context-dependent effects of leptin on immune responses (). (M Kamel et al., 2023) contribute to this discussion by examining the association between serum leptin and disease activity in Egyptian SLE patients, reiterating the potential of leptin as a biomarker for disease progression, particularly in those with nephritis ((M Kamel et al., 2023)). **Conclusion:** In conclusion, the collected literature underscores the critical role of leptin in the pathogenesis of SLE, positioning it as both a biomarker and a potential therapeutic target. The evidence suggests that elevated leptin levels contribute to the dysregulation of immune responses characteristic of SLE, particularly through their impact on Treg populations and inflammatory pathways. However, the complexity of leptin's role necessitates further investigation to fully elucidate its mechanisms and implications for therapeutic interventions in SLE.

Keywords: Role, Leptin, Pathogenesis, Systemic Lupus Erythematosus

INTRODUCTION

The exploration of leptin's role in the pathogenesis of systemic lupus erythematosus (SLE) has garnered increasing attention in recent years, as evidenced by a series of studies that delve into the multifaceted relationships between this adipokine and autoimmune processes. highlight the implication of leptin in SLE, suggesting that it not only serves as a marker of inflammatory status but also plays a significant role in modulating immune responses. Their findings indicate that leptin deficiency in mouse models protects against the development of autoantibodies and renal disease, thereby establishing leptin as a critical factor influencing the progression of SLE.

Building upon this foundation, (Cordero-Barreal et al., 2021) report that plasma leptin levels are elevated in SLE patients compared to controls, and they demonstrate that leptin overexpression correlates with a decrease in regulatory T cells (Tregs).

The authors argue that inhibiting leptin could enhance Treg expansion and potentially mitigate autoimmune responses in SLE patients. Their experimental results with mouse models further substantiate the notion that elevated leptin levels accelerate lupus development, reinforcing the hypothesis that leptin is a key player in the disease's pathogenesis.

(B. Taylor, 2021) expands on these findings by discussing the pro-inflammatory effects of leptin, particularly its role in promoting Th1 and Th17 responses while simultaneously reducing Treg activity. This dysregulation is echoed in various autoimmune diseases, including SLE. The author notes that leptin-deficient mice exhibit protection against autoimmunity, emphasizing the correlation between elevated leptin levels and increased disease activity in models of SLE. These observations suggest that leptin antagonism could be a viable therapeutic strategy in managing SLE.

(Giardullo et al., 2021) contribute to the discourse by examining the relationship between leptin and SLE through experimental models, showing that leptin's presence correlates with the development of autoantibodies and exacerbation of kidney disease. Their work also highlights the potential of serum leptin levels as biomarkers for disease progression, particularly in female patients with SLE. This perspective aligns with the growing body of evidence that positions leptin as a significant factor in the pathophysiology of SLE.

Synthesize existing literature in their systematic review, indicating that the relationship between leptin and SLE remains complex and multifaceted. By employing rigorous search methodologies, they underscore the necessity for a comprehensive understanding of leptin's immunomodulatory effects to clarify its role in SLE.

Finally, (M Kamel et al., 2023) investigate the association of serum leptin and adiponectin levels with disease activity in Egyptian

patients suffering from SLE. Their findings indicate that elevated leptin levels, particularly in patients with nephritis, may serve as important biomarkers for disease progression, further supporting the notion that leptin is intricately linked to the inflammatory processes characteristic of SLE.

Together, these studies elucidate the critical role of leptin in the pathogenesis of SLE, highlighting its potential as both a biomarker and a therapeutic target in managing this complex autoimmune disorder.

LITERATURE REVIEW

The article "Obesity, Fat Mass and Immune System: Role for Leptin" by Francisco et al. (Francisco et al., 2018) provides a comprehensive exploration of the role of leptin, an adipokine, in the pathogenesis of systemic lupus erythematosus (SLE). The authors synthesize various studies that highlight the intricate relationship between leptin levels, immune system modulation, and the development of autoimmune conditions, particularly SLE.

One of the key insights presented is the correlation between leptin and cardiovascular risk in SLE patients, suggesting that elevated leptin levels may exacerbate cardiovascular complications commonly observed in this population. The authors reference experimental findings where leptin deficiency in murine models resulted in a notable decrease in the development of autoantibodies and renal disease, alongside an increase in regulatory T (Treg) cells compared to wild-type controls. This finding underscores the potential protective role of leptin deficiency against the autoimmune processes characteristic of SLE.

Furthermore, the article discusses the role of apoptotic cells as a significant source of self-antigens that perpetuate autoimmune responses in SLE. The implication is that leptin may facilitate the immune system's response to these self-antigens, thereby contributing to the disease's pathogenesis. The authors effectively argue that leptin serves not only as a marker of metabolic status but also as a critical modulator of

inflammatory responses, linking obesity and metabolic disorders to inflammatory pathologies, including SLE.

The authors also acknowledge the complexity of the leptin network and the necessity for further research to fully elucidate leptin's immunomodulatory mechanisms across different immune cell types. They emphasize that despite the promising findings, the potential side effects and the intricate dynamics of leptin's role in immune regulation remain significant challenges in the context of drug discovery for SLE.

The article "An Update on the Role of Leptin in the Immuno-Metabolism of Cartilage" by Cordero-Barreal et al. (Cordero-Barreal et al., 2021) provides a comprehensive examination of the implications of leptin in the context of systemic lupus erythematosus (SLE), an autoimmune disease characterized by diverse organ involvement and significant nervous system implications. The authors present compelling evidence indicating that leptin levels are significantly elevated in the plasma of

SLE patients compared to healthy controls, which underscores the potential role of this adipokine in the pathogenesis of the disease.

A critical aspect of the findings is the relationship between leptin levels and T regulatory (Treg) cell populations in SLE patients. The article suggests that higher leptin concentrations are associated with a decrease in Treg cells, which are crucial for maintaining immune tolerance and preventing autoimmunity. This observation implies that leptin may contribute to the dysregulation of the immune system in SLE, potentially exacerbating the autoimmune response (Cordero-Barreal et al., 2021).

The authors also discuss experimental data from mouse models, highlighting that increased leptin levels correlate with heightened IgG secretion following pristane injection, a known trigger for lupus-like disease in these models. The accelerated disease progression observed in leptin-overexpressing mice further supports the hypothesis

that leptin plays a pivotal role in promoting lupus pathogenesis. Conversely, leptin-deficient mice or those treated with leptin antagonists did not exhibit a response to pristane, reinforcing the notion that leptin is integral to the autoimmune processes in SLE (Cordero-Barreal et al., 2021).

While the article effectively outlines the mechanistic insights into how leptin may influence SLE development, it also raises important questions regarding therapeutic interventions targeting leptin signaling pathways. The potential for leptin inhibition as a strategy to mitigate autoimmunity in SLE patients is an intriguing avenue that warrants further exploration. However, the authors could have elaborated on the translational aspects of their findings, particularly how these insights could inform clinical practices or the development of new therapeutic agents.

The article "The complex role of adipokines in obesity, inflammation, and autoimmunity" by Erin B. Taylor (B. Taylor, 2021) provides a comprehensive

examination of the multifaceted role of leptin in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Taylor highlights the protective effects observed in mice deficient in leptin signaling, which do not develop autoantibodies and exhibit elevated regulatory T cell (Treg) responses when SLE is induced. This finding underscores the potential importance of leptin as a pro-inflammatory mediator in the context of autoimmune pathogenesis.

The article emphasizes the relationship between leptin levels and disease activity in SLE, as evidenced by the spontaneous NZBWF1 mouse model, where elevated leptin levels correlated with increased disease severity. This observation aligns with clinical studies indicating that SLE patients generally exhibit higher circulating leptin levels. The inverse correlation between leptin levels and Treg frequency, as demonstrated by Wang et al., suggests that leptin may contribute to the dysregulation of T cell subsets, particularly the promotion of pathogenic Th1 and Th17 responses while concurrently

diminishing Treg activity. This dysregulation is a hallmark of many autoimmune diseases, including SLE.

Moreover, Taylor discusses the temporal dynamics of leptin in relation to disease onset, noting a surge in leptin levels preceding acute symptoms in experimental models of multiple sclerosis (EAE). This finding raises intriguing questions about the role of leptin as a biomarker for disease activity and its potential as a therapeutic target. The article also highlights the complexities surrounding leptin's role in other autoimmune conditions, such as rheumatoid arthritis (RA), where its effects on inflammation are context-dependent.

Despite the valuable insights presented, the article acknowledges the existing gaps in understanding the precise mechanisms by which leptin influences autoimmune pathogenesis. The discrepancies in leptin levels observed across different studies, particularly in RA, indicate that further research is necessary to elucidate the exact role of leptin in these diseases. Additionally, the

potential for leptin antagonism as a therapeutic strategy in SLE and other autoimmune disorders remains an area ripe for exploration.

The article titled "Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases" by Giardullo et al. (Giardullo et al., 2021) provides significant insights into the role of leptin in the context of systemic lupus erythematosus (SLE). The authors highlight the complex interplay between leptin, an adipokine, and the pathogenesis of SLE, particularly noting its impact on the immune response and disease progression.

The study referenced within the article, conducted by Lourenço et al., presents compelling evidence regarding the differential effects of leptin on the development of lupus-like disease in mice. In their experiment, two groups of mice, one leptin-deficient and the other wild-type, were subjected to pristine-induced SLE. The findings revealed that the wild-type group, characterized by normal leptin levels,

developed a lupus-like condition accompanied by elevated levels of immunoglobulin G (IgG), antinuclear antibodies (ANA), and extractable nuclear antigens (ENA). In contrast, the leptin-deficient group did not show similar signs of autoantibody development. This stark contrast suggests that leptin may be a critical factor in the pathogenesis of SLE, potentially influencing the immune system's response and contributing to the autoimmune processes characteristic of the disease.

Furthermore, the article discusses the implications of high leptin levels on kidney disease progression in SLE patients. The authors emphasize that elevated leptin not only correlates with the severity of kidney involvement but may also exacerbate the overall disease state. This connection underscores the importance of leptin as a potential biomarker for disease activity and progression in SLE, particularly in premenopausal women, as noted by Demir et al. The suggestion that leptin levels could serve as a marker for subclinical atherosclerosis in this demographic adds another layer of

complexity to its role in SLE, indicating that leptin may be implicated in cardiovascular risks associated with the disease.

The article titled "The Role of Leptin in Systemic Lupus Erythematosus: Is It Still a Mystery?" by Villa et al. presents a systematic review that explores the intricate relationship between leptin and systemic lupus erythematosus (SLE). The authors meticulously followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, ensuring a rigorous methodological framework for their literature search.

The review highlights the significance of leptin, a hormone primarily produced by adipose tissue, in the context of autoimmune diseases, particularly SLE. The authors conducted comprehensive searches across various databases, including PubMed, Cochrane Library, Google Scholar, ScienceDirect, and Epistemonikos, employing a systematic approach using specific keywords and Medical Subject Headings (MeSH) terms. This

thorough methodology underscores the authors' commitment to capturing a wide array of studies relevant to the role of leptin in SLE.

One of the critical insights from the review is the potential dual role of leptin as both a pro-inflammatory and regulatory factor in SLE pathogenesis. The authors discuss how elevated leptin levels have been observed in SLE patients, which could contribute to the disease's inflammatory processes. This association is particularly relevant given that SLE is characterized by a dysregulated immune response, and leptin's influence on T cell activation and differentiation may exacerbate this condition.

Furthermore, the review addresses the complexity of leptin signaling pathways and their interactions with other cytokines and immune mediators. The authors note that while leptin may promote inflammation, it could also play a role in the resolution of immune responses, indicating that its function in SLE may not be entirely

straightforward. This nuanced perspective is essential as it encourages further investigation into the context-dependent effects of leptin in autoimmune pathology.

However, the article also acknowledges the limitations in the current body of literature regarding leptin and SLE. The authors point out that many studies have small sample sizes and varying methodologies, which can lead to inconsistencies in findings. This variability highlights the need for larger, multicentric studies to better understand the role of leptin in SLE and its potential as a therapeutic target.

The article titled "High serum leptin and adiponectin levels as biomarkers of disease progression in Egyptian patients with active systemic lupus erythematosus" by Kamel et al. (M Kamel et al., 2023) provides valuable insights into the complex role of leptin and adiponectin in systemic lupus erythematosus (SLE). The authors highlight the significance of these adipokines as potential biomarkers for disease progression, particularly

in the context of their inflammatory roles.

The study emphasizes that SLE is a chronic autoimmune disease characterized by dysregulated immune responses, marked by an imbalance between pro-inflammatory and anti-inflammatory cytokines. Leptin, a non-glycosylated peptide produced predominantly by adipocytes, is identified as a cytokine-like immune modulator that may influence inflammatory responses in SLE. The authors note that elevated serum leptin levels are frequently observed in SLE patients, especially those with lupus nephritis, suggesting a potential link between leptin and the severity of the disease (M Kamel et al., 2023).

Moreover, the article discusses adiponectin, another adipokine produced by adipose macrophages, which exhibits both anti-inflammatory and pro-inflammatory properties. The dual role of adiponectin complicates its interpretation as a biomarker, as its higher circulating levels in SLE patients are associated with

inflammatory markers. This finding indicates that while adiponectin may have protective effects, its elevation in SLE could also reflect underlying inflammatory processes (M Kamel et al., 2023).

The authors critically address the variability in leptin and adiponectin levels among SLE patients, linking these fluctuations to demographic factors, body mass index (BMI), dietary components, and disease activity. This variability underscores the need for more standardized approaches in assessing these biomarkers in clinical settings. The lack of a clear explanation for the elevated levels of leptin and adiponectin further indicates the complexity of SLE pathogenesis and the multifactorial nature of these adipokines.

CONCLUSION

The literature presents a compelling examination of the role of leptin in the pathogenesis of systemic lupus erythematosus (SLE), highlighting its multifaceted involvement in immune modulation and disease progression. A consistent theme across the studies is the

elevation of plasma leptin levels in SLE patients, which correlates with increased disease activity and the dysregulation of immune responses, particularly concerning regulatory T cells (Tregs) and pro-inflammatory T cell subsets.

Initial findings by (Francisco et al., 2018) suggest that leptin not only acts as an inflammatory marker but also plays a significant role in modulating immune responses, with leptin deficiency in mouse models protecting against autoantibody production and renal disease. This protective effect underscores the potential importance of leptin as a contributing factor to SLE pathogenesis ((Francisco et al., 2018)). Building on this, (Cordero-Barreal et al., 2021) further elucidate the relationship between elevated leptin levels and reduced Treg populations in SLE patients, suggesting that inhibition of leptin may enhance Treg expansion and mitigate autoimmune responses ((Cordero-Barreal et al., 2021)).

(B. Taylor, 2021) expands on the pro-inflammatory effects of

leptin, particularly its role in promoting Th1 and Th17 responses while diminishing Treg activity, a dysregulation observed in various autoimmune diseases, including SLE. The author emphasizes the therapeutic potential of leptin antagonism in managing SLE ((B. Taylor, 2021)). (Giardullo et al., 2021) reinforce this perspective by demonstrating that leptin's presence correlates with the development of autoantibodies and exacerbation of kidney disease, framing serum leptin levels as potential biomarkers for disease progression ((Giardullo et al., 2021)).

The systematic review by highlights the complexity of leptin's role, indicating that it may function both as a pro-inflammatory and regulatory factor in SLE. This duality suggests that further research is needed to clarify the context-dependent effects of leptin on immune responses (). (M Kamel et al., 2023) contribute to this discussion by examining the association between serum leptin and disease activity in Egyptian SLE patients, reiterating the potential of leptin as a biomarker for

disease progression, particularly in those with nephritis ((M Kamel et al., 2023)).

In conclusion, the collected literature underscores the critical role of leptin in the pathogenesis of SLE, positioning it as both a biomarker and a potential therapeutic target. The evidence suggests that elevated leptin levels contribute to the dysregulation of immune responses characteristic of SLE, particularly through their impact on Treg populations and inflammatory pathways. However, the complexity of leptin's role necessitates further investigation to fully elucidate its mechanisms and implications for therapeutic interventions in SLE.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -

Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCE

1. Cordero-Barreal, A., González-Rodríguez, M., Ruiz-Fernández, C., Ait Eldjoudi, D., Ramadan Farrag AbdElHafez, Y., Lago, F., Conde, J., Gómez, R., Angel González-Gay, M., Mobasher, A., Pino, J., & Gualillo, O., 2021. An Update on the Role of Leptin in the Immuno-Metabolism of Cartilage. ncbi.nlm.nih.gov
2. B. Taylor, E., 2021. The complex role of adipokines in obesity, inflammation, and autoimmunity. ncbi.nlm.nih.gov
3. Giardullo, L., Corrado, A., Maruotti, N., Cici, D., Mansueto, N., & Paolo Cantatore, F., 2021. Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases. ncbi.nlm.nih.gov
4. M Kamel, S., E (Mervat I) Abdel Azeem (Abd Elazeem), M., A Mohamed, R., M Kamel, M., & A Abdel Aleem (Abdelaleem), E., 2023. High serum leptin and adiponectin levels as biomarkers of disease progression in Egyptian patients with active systemic lupus erythematosus. ncbi.nlm.nih.gov
5. Francisco, V., Pino, J., Campos Cabaleiro, V., Ruiz Fernández, C., Mera, A., Ángel González-Gay Mantecón, M., Gómez, R., & Gualillo, O., 2018. Obesity, Fat Mass and Immune System: Role for Leptin. [PDF]